Bioavailable Testosterone: Evidence-Based Ways to Improve Your Levels

What Bioavailable Testosterone Actually Measures

Bioavailable testosterone is the sum of free testosterone (1-3% of total T) and the portion loosely bound to albumin (roughly 25-50%), which dissociates easily at capillary beds and enters target cells. The tightly bound fraction, attached to sex hormone-binding globulin, cannot cross cell membranes under normal physiological conditions. A man with a total testosterone of 500 ng/dL but elevated SHBG may have a bioavailable T equivalent to someone with a total T of 300 ng/dL and normal SHBG. That difference matters clinically.

The 2018 Endocrine Society Clinical Practice Guideline recommends measuring total testosterone first thing in the morning on two separate days, then calculating free or bioavailable T when SHBG abnormalities are suspected 1. The Vermeulen equation, validated against equilibrium dialysis, remains the most widely accepted calculation method 2. Equilibrium dialysis is the gold standard for free T measurement, but it is expensive and not widely available in routine clinical practice, which is why calculated bioavailable T fills a practical gap 3.

Normal Bioavailable Testosterone Ranges by Age

Reference ranges depend on the assay and the lab. General population-based data from the Framingham Heart Study and the European Male Aging Study (EMAS) provide useful benchmarks. In EMAS (N=3,369 community-dwelling men aged 40-79), mean total testosterone declined by approximately 0.4% per year, while free and bioavailable T declined faster because SHBG rises with age 4.

Approximate adult male reference ranges commonly cited:

• Ages 20-29: bioavailable T roughly 200-680 ng/dL
• Ages 30-39: roughly 180-620 ng/dL
• Ages 40-49: roughly 160-560 ng/dL
• Ages 50-59: roughly 140-500 ng/dL
• Ages 60-69: roughly 120-450 ng/dL
• Ages 70+: roughly 100-380 ng/dL

These numbers vary across laboratories. Mayo Clinic and Quest Diagnostics each publish their own reference intervals, and the threshold for "low" depends on the clinical context and symptom burden. The Endocrine Society guideline defines hypogonadism as a total T consistently below 300 ng/dL (or below the lab-specific lower limit) combined with signs and symptoms 1.

Why SHBG Is the Variable You Cannot Ignore

SHBG acts as a binding reservoir. When SHBG rises, more testosterone becomes sequestered and unavailable to tissues, lowering bioavailable T even when total T appears adequate. SHBG increases with aging, hyperthyroidism, liver disease, estrogen exposure, and anticonvulsant use. It decreases with obesity, insulin resistance, hypothyroidism, nephrotic syndrome, and androgen use.

A 2010 analysis from the Massachusetts Male Aging Study (N=1,667) found that SHBG increased by 1.3% per year in community-dwelling men, accounting for much of the age-related decline in bioavailable testosterone independent of changes in total T 5. Clinicians who only check total testosterone will miss cases where elevated SHBG creates a functional deficiency.

"Total testosterone alone is insufficient for diagnosing androgen deficiency when SHBG concentrations are abnormal," the Endocrine Society guideline states. "Measurement of free or bioavailable testosterone is recommended in these situations" 1.

Body Composition: The Largest Modifiable Lever

Adipose tissue aromatizes testosterone to estradiol via the enzyme aromatase, simultaneously lowering T and raising estrogen, which in turn stimulates hepatic SHBG production in a complex feedback loop. Excess visceral fat also drives insulin resistance, which suppresses SHBG independently. The net effect: obese men lose bioavailable testosterone from both ends.

Weight loss reverses this. A meta-analysis of 24 studies (N=1,489 men) published in Clinical Endocrinology found that lifestyle-induced weight loss increased total testosterone by a mean of 2.9 nmol/L (approximately 84 ng/dL) per 10% reduction in body weight 6. The testosterone increase was proportional to the degree of fat loss, not to the type of diet used.

Bariatric surgery produces even larger gains. A prospective study of men undergoing Roux-en-Y gastric bypass (N=58) showed that total T increased from a mean of 251 ng/dL to 458 ng/dL at 12 months, with bioavailable T rising correspondingly 7. Not every man needs surgery. A caloric deficit producing 0.5-1.0 kg of weekly fat loss, combined with resistance training to preserve lean mass, is the first-line recommendation.

Resistance Training and Its Direct Hormonal Effects

Resistance exercise acutely raises testosterone for 15-60 minutes post-session, but the chronic adaptation matters more. A 12-week randomized trial in previously sedentary men (N=44, ages 40-60) found that a progressive resistance training program increased resting total testosterone by 15% and free testosterone by 21% compared to controls 8. Compound movements (squats, deadlifts, bench press) using loads above 70% of one-repetition maximum produced the most reliable hormonal responses.

Overtraining does the opposite. Endurance athletes running more than 60-70 miles per week frequently present with exercise-associated hypogonadism, a condition where cortisol elevation and energy deficiency suppress the hypothalamic-pituitary-gonadal (HPG) axis 9. The dose-response curve for exercise and testosterone is an inverted U: moderate-to-high intensity resistance training sits at the peak, while excessive endurance volume tips the balance toward suppression.

Sleep: The Overlooked Hormonal Regulator

Testosterone secretion follows a circadian pattern, peaking during early morning sleep stages. A controlled experiment at the University of Chicago restricted healthy young men (N=10, ages 24 ± 4) to five hours of sleep per night for one week. Daytime testosterone levels dropped 10-15% relative to baseline, with the largest declines occurring in the afternoon 10.

"The magnitude of the effect is comparable to aging 10-15 years," noted lead investigator Eve Van Cauter, PhD, in the accompanying commentary. Seven to nine hours of sleep per night is the minimum for preserving normal HPG axis function. Obstructive sleep apnea (OSA) independently suppresses testosterone through intermittent hypoxia and fragmented sleep architecture. Treatment of OSA with continuous positive airway pressure (CPAP) has shown inconsistent testosterone recovery in trials, suggesting that weight loss may be required alongside CPAP for a full hormonal response 11.

Micronutrient Repletion: Zinc, Vitamin D, and Magnesium

Three micronutrients have direct evidence linking deficiency to low testosterone.

Zinc. A landmark study by Prasad et al. demonstrated that dietary zinc restriction in young men reduced serum testosterone by 75% over 20 weeks. Zinc supplementation (30 mg/day elemental zinc) in marginally deficient elderly men raised testosterone from 8.3 nmol/L to 16.0 nmol/L over six months 12. Men on proton pump inhibitors, vegetarians, and heavy exercisers are at highest risk for zinc depletion.

Vitamin D. A randomized, double-blind, placebo-controlled trial (N=165 overweight men) found that supplementation with 3 to 332 IU of vitamin D daily for one year increased total testosterone by 3.0 nmol/L compared to placebo in men whose baseline 25(OH)D was below 20 ng/mL 13. The effect was absent in men who were already vitamin D-sufficient, indicating that supplementation works by correcting deficiency, not by pharmacologically boosting testosterone above physiologic levels.

Magnesium. A study in 399 older men (mean age 73) found a significant positive correlation between serum magnesium and both total and free testosterone after adjusting for confounders 14. Interventional data remain limited, but correcting documented magnesium deficiency is reasonable given its low cost and favorable safety profile.

Pharmacologic Options When Lifestyle Is Not Enough

When bioavailable testosterone remains low despite optimized body composition, sleep, and nutrient status, pharmacologic intervention becomes appropriate. The choice depends on age, fertility goals, and symptom severity.

Testosterone replacement therapy (TRT). The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials enrolling 790 men aged 65 and older with total T <275 ng/dL, demonstrated that one year of transdermal testosterone gel improved sexual function, walking distance, mood, and bone mineral density compared to placebo 15. Bioavailable T increased into the mid-normal range for younger men. TRT is the standard of care for confirmed hypogonadism but suppresses spermatogenesis and is not suitable for men actively pursuing fertility.

Clomiphene citrate (off-label). This selective estrogen receptor modulator blocks negative feedback at the hypothalamus, increasing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) output and thereby stimulating endogenous testosterone production. A retrospective analysis of 86 hypogonadal men treated with clomiphene 25-50 mg every other day showed a mean increase in total testosterone from 228 ng/dL to 612 ng/dL over a median of 19 months, with preserved sperm counts 16.

Enclomiphene. The purified trans-isomer of clomiphene, enclomiphene (marketed as Androxal in some jurisdictions), showed similar testosterone-raising effects with a potentially cleaner side-effect profile in phase III trials. A 2014 study (N=73) found enclomiphene 25 mg daily raised morning total T from a mean of 232 ng/dL to 465 ng/dL at 16 weeks while maintaining sperm concentration 17.

Anastrozole (off-label). In men with obesity-related hypogonadism and elevated estradiol, the aromatase inhibitor anastrozole (1 mg daily) has been shown to increase testosterone and lower estradiol. A small RCT (N=42 hypogonadal obese men) demonstrated a mean rise in total T from 252 ng/dL to 458 ng/dL after six months 18. The Endocrine Society does not recommend aromatase inhibitors as first-line therapy for hypogonadism but acknowledges their use in select cases with elevated aromatase activity.

What Lowers Bioavailable Testosterone and How to Address It

Several common medications and conditions suppress bioavailable T:

• Opioids. Chronic opioid use causes hypogonadism in 50-90% of men on long-term therapy through central HPG axis suppression 19. Dose reduction or rotation should be considered when clinically feasible.
• Glucocorticoids. Prednisone doses above 7.5 mg daily suppress gonadotropins. Tapering to the lowest effective dose protects the HPG axis.
• Type 2 diabetes. Up to 25% of men with T2D have low total testosterone 20. Glycemic control through GLP-1 receptor agonists, SGLT2 inhibitors, or metformin (the latter modestly raises SHBG) can partially restore levels.
• Excessive alcohol intake. More than 3-4 drinks per day directly inhibits testicular Leydig cell function and increases hepatic SHBG synthesis. Reducing intake below 14 drinks per week removes this suppressive signal.

Monitoring: How Often and What to Track

After initiating any intervention (lifestyle or pharmacologic), recheck bioavailable testosterone at 8-12 weeks. The minimum panel should include total testosterone (morning draw, fasting), SHBG, albumin, calculated free and bioavailable T, LH, FSH, estradiol, hematocrit, and PSA (in men over 40). For men on TRT, the Endocrine Society recommends monitoring hematocrit every 6-12 months because exogenous testosterone stimulates erythropoiesis and hematocrit above 54% requires dose adjustment or phlebotomy 1.

Target bioavailable testosterone on therapy should fall within the age-specific reference range, typically 150-500 ng/dL for men aged 40-65. Supraphysiologic levels do not confer additional clinical benefit and increase cardiovascular and polycythemia risk. The TRAVERSE trial (N=5,246 men, mean age 63) confirmed that TRT dosed to achieve mid-normal T levels did not increase major adverse cardiovascular events compared to placebo over a mean follow-up of 33 months 21.